172 related articles for article (PubMed ID: 15578952)
1. Application of decoy oligodeoxynucleotides-based approach to renal diseases.
Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
Curr Drug Targets; 2004 Nov; 5(8):717-33. PubMed ID: 15578952
[TBL] [Abstract][Full Text] [Related]
2. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design.
Tomita N; Ogihara T; Morishita R
Curr Drug Targets; 2003 Nov; 4(8):603-8. PubMed ID: 14577649
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.
Tomita N; Kashihara N; Morishita R
Clin Exp Nephrol; 2007 Mar; 11(1):7-17. PubMed ID: 17384993
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
Kawamura I; Morishita R; Tomita N; Lacey E; Aketa M; Tsujimoto S; Manda T; Tomoi M; Kida I; Higaki J; Kaneda Y; Shimomura K; Ogihara T
Gene Ther; 1999 Jan; 6(1):91-7. PubMed ID: 10341880
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases.
Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
Curr Drug Targets; 2003 May; 4(4):339-46. PubMed ID: 12699354
[TBL] [Abstract][Full Text] [Related]
6. [Oligonucleotide-based therapy as a potential new pharmacotherapy].
Morishita R
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):123-30. PubMed ID: 10876797
[TBL] [Abstract][Full Text] [Related]
7. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease.
Morishita R; Higaki J; Tomita N; Ogihara T
Circ Res; 1998 Jun; 82(10):1023-8. PubMed ID: 9622154
[TBL] [Abstract][Full Text] [Related]
8. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.
Nakamura T; Morishita R; Asai T; Tsuboniwa N; Aoki M; Sakonjo H; Yamasaki K; Hashiya N; Kaneda Y; Ogihara T
Gene Ther; 2002 Apr; 9(8):488-94. PubMed ID: 11948373
[TBL] [Abstract][Full Text] [Related]
9. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats.
Cao CC; Ding XQ; Ou ZL; Liu CF; Li P; Wang L; Zhu CF
Kidney Int; 2004 Mar; 65(3):834-45. PubMed ID: 14871403
[TBL] [Abstract][Full Text] [Related]
10. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice.
Kawamura I; Morishita R; Tsujimoto S; Manda T; Tomoi M; Tomita N; Goto T; Ogihara T; Kaneda Y
Gene Ther; 2001 Jun; 8(12):905-12. PubMed ID: 11426330
[TBL] [Abstract][Full Text] [Related]
11. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis.
Tomita N; Kim JY; Gibbons GH; Zhang L; Kaneda Y; Stahl RA; Ogborn M; Venderville B; Morishita R; Baran D; Dzau VJ
Int J Mol Med; 2004 May; 13(5):629-36. PubMed ID: 15067361
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases.
Tomita N; Ogihara T; Morishita R
Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):463-70. PubMed ID: 15030273
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors.
Nakashima H; Aoki M; Miyake T; Kawasaki T; Iwai M; Jo N; Oishi M; Kataoka K; Ohgi S; Ogihara T; Kaneda Y; Morishita R
Circulation; 2004 Jan; 109(1):132-8. PubMed ID: 14662712
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of NF-kappaB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy.
Kim KH; Lee ES; Cha SH; Park JH; Park JS; Chang YC; Park KK
Exp Mol Pathol; 2009 Apr; 86(2):114-20. PubMed ID: 19118545
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs?
Morishita R; Aoki M; Kaneda Y
Curr Drug Targets; 2000 Jul; 1(1):15-23. PubMed ID: 11475534
[TBL] [Abstract][Full Text] [Related]
17. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
Tomita N; Horiuchi M; Tomita S; Gibbons GH; Kim JY; Baran D; Dzau VJ
Am J Physiol; 1998 Aug; 275(2):F278-84. PubMed ID: 9691019
[TBL] [Abstract][Full Text] [Related]
18. [Transfection of nuclear factor-kappaB decoy oligodeoxynucleotides prevents ischemic acute renal failure in rats].
Cao CC; Ding XQ; Ou ZL; Liu CF; Li P; Wang L; Zhu CF
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1597-602. PubMed ID: 14642117
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic applications of decoy oligonucleotides.
Tomita N; Morishita R; Tomita T; Ogihara T
Curr Opin Mol Ther; 2002 Apr; 4(2):166-70. PubMed ID: 12044038
[TBL] [Abstract][Full Text] [Related]
20. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells.
Ahn JD; Kim CH; Magae J; Kim YH; Kim HJ; Park KK; Hong S; Park KG; Lee IK; Chang YC
Biochem Biophys Res Commun; 2003 Oct; 310(4):1048-53. PubMed ID: 14559221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
